Variables | Overall | survivor | Non-survivor | OR | p |
---|---|---|---|---|---|
n = 79 | n = 42 | n = 37 | |||
Patient background | |||||
 Age | 74 (62 to 86) | 75 (64 to 86) | 74 (62 to 85) | 1.113 | 0.374 |
 Sex | 66 | 32 | 34 | 3.333 | 0.126 |
 Man (%) | 83.54% | 76.19% | 91.89% |  |  |
 Smoking history | 61 | 31 | 30 | 1.428 | 0.597 |
  Yes (%) | 77.22% | 73.81% | 81.08% |  |  |
 Current smoker | 13 | 7 | 6 | 1.128 | 0.973 |
  Yes (%) | 16.46% | 16.67% | 14.29% |  |  |
 Time to diagnosis of IIPs | 33.25 ± 38.39 | 31.20 ± 35.24 | 37.76 ± 42.36 | 2.176 | 0.124 |
Symptoms | |||||
 High fever | 43 | 23 | 20 | 1.012 | 0.949 |
  Yes (%) | 54.43% | 54.76% | 54.05% |  |  |
 Sore throat | 35 | 22 | 13 | 3.841 | 0.132 |
  Yes (%) | 44.13% | 52.38% | 35.14% |  |  |
 Worsening cough | 50 | 27 | 23 | 1.011 | 0.969 |
  Yes (%) | 63.29% | 64.28% | 62.16% |  |  |
 Worsening dyspnea | 75 | 39 | 36 | 1.618 | 0.701 |
  Yes (%) | 94.94% | 92.85% | 97.29% |  |  |
Pre-existing CF-IIPs | Â | Â | Â | 0.409 | 0.815 |
 IPF | 59 | 33 | 26 |  |  |
 UCIP | 20 | 9 | 11 |  |  |
Prior treatment | Â | Â | Â | 2.793 | 0.593 |
 No treatment | 47 | 28 | 19 |  |  |
 Corticosteroid | 9 | 4 | 5 |  |  |
 Corticosteroid + IS | 6 | 2 | 4 |  |  |
 Pirfenidone | 9 | 5 | 4 |  |  |
 Nintedanib | 4 | 2 | 2 |  |  |
 Corticosteroid + Nintedanib | 4 | 1 | 3 |  |  |
Clinical AE-IIPs types | Â | Â | Â | 13.138 | 0.0009 |
 Idiopathic | 34 | 12 | 22 |  |  |
 Infection-triggered | 25 | 20 | 5 |  |  |
 Non-infection-triggered | 20 | 10 | 10 |  |  |
HRCT patterns at AE-IIPs onset | Â | Â | Â | 16.011 | 0.0003 |
 Diffuse | 34 | 9 | 25 |  |  |
 Multifocal | 14 | 12 | 2 |  |  |
 Peripheral | 31 | 21 | 10 |  |  |
Pulmonary function | |||||
 P/F ratio | 168 (83.2 to 344.1) n = 79 | 246 (103 to 362) n = 42 | 132 (67 to 339) n = 37 | 11.510 | 0.0007 |
 VC (%) | 2.49 (1.33 to 3.05) n = 39 | 2.43 (0.95 to 3.45) n = 23 | 2.58 (1.87 to 3.45) n = 16 | 2.329 | 0.127 |
 VC (L) | 70.70 (44.60 to 90.22) n = 39 | 69.55 (38.50 to 93.55) n = 23 | 71.21 (48.63 to 99.74) n = 16 | 0.655 | 0.418 |
 FVC (%) | 2.35 (0.94 to 3.01) n = 39 | 2.35 (0.89 to 3.45) n = 23 | 2.38 (1.84 to 3.47) n = 16 | 2.212 | 0.136 |
 FVC (L) | 65.55 (39.85 to 84.02) n = 39 | 65.33 (35.58 to 86.82) n = 23 | 67.51 (50.20 to 86.00) n = 16 | 1.084 | 0.297 |
 DLco (mL/min/mmHg) | 7.29 (3.85 to 11.35) n = 30 | 7.63 (4.33 to 11.76) n = 16 | 6.79 (3.68 to 11.45) n = 14 | 0.080 | 0.776 |
 DLco (%) | 29.90 (16.55 to 40.02) n = 30 | 31.5 (17.68 to 51.08) n = 16 | 26.35 (15.75 to 44.70) n = 14 | 0.356 | 0.551 |
Serum markers | |||||
 KL-6 (IU/L) | 1117 (572 to 2701) n = 79 | 1086 (569 to 2882) n = 42 | 1166 (583 to 2585) n = 37 | 28.571 | 0.938 |
 SP-D (mg/dL) | 364 (45 to 2711) n = 63 | 362 (148 to 987) n = 36 | 370 (76 to 1382) n = 27 | 1.612 | 0.424 |
 LDH (IU/L) | 365 (193 to 539) n = 79 | 350 (249 to 539) n = 42 | 368 (228 to 540) n = 37 | 5.586 | 0.671 |
 WBC (/μL) | 10,700 (6300 to 15,400) n = 79 | 10,690 (5960 to 15,900) n = 42 | 11,300 (8600 to 14,600) n = 37 | 4.037 | 0.620 |
 CRP (mg/dL) | 8.5 (0.7 to 25) n = 79 | 7.5 (1.98 to 24.65) n = 42 | 8.8 (1.86 to 21.76) n = 37 | 37.037 | 0.987 |
 Procalcitonin (ng/mL) | 0.12 (0.01 to 0.74) n = 70 | 0.12 (0.01 to 0.74) n = 38 | 0.10 (0.01 to 0.68) n = 32 | 1.021 | 0.878 |
 D-dimer (mg/dL) | 3.6 (1.38 to 74.2) n = 74 | 3.1 (1.27 to 17.18) n = 41 | 4.9 (1.88 to 33.32) n = 33 | 2.002 | 0.157 |